by Andrew M. Brunner, MD; Courtney D. DiNardo, MD, MSCE; and Rami S. Komrokji, MD
Advancements in immuno-oncology have resulted in the discovery and testing of novel immune targets in myelodysplastic syndrome (MDS) and acute myel......READ MORE
by Andrew M. Brunner, MD; Courtney D. DiNardo, MD, MSCE; and Rami S. Komrokji, MD
Researchers hope to employ novel strategies to extend remissions, prevent relapse, and improve survival outcomes in high-risk myelodysplastic syndr......READ MORE
by Andrew M. Brunner, MD; Courtney D. DiNardo, MD, MSCE; and Rami S. Komrokji, MD
Next-generation sequencing (NGS) is now more standard in the evaluation of myelodysplastic syndrome (MDS). Genomic features, such as mutations in T......READ MORE
by Andrew M. Brunner, MD; Courtney D. DiNardo, MD, MSCE; and Rami S. Komrokji, MD
Our featured experts review the current progress toward and future directions for the development of lower-intensity treatment regimens for patient......READ MORE
Patients with acute myeloid leukemia (AML) have more options for treatment today than in the past. Our featured expert highlights this progress, no......READ MORE
Patients who are ineligible for intensive chemotherapy are in need of effective and well-tolerated alternatives. Our featured expert describes the ......READ MORE
